4.4 Article

Gene Expression Patterns of Osteopontin Isoforms and Integrins in Malignant Melanoma

Related references

Note: Only part of the references are listed.
Article Oncology

Molecular Alterations Associated with Acquired Drug Resistance during Combined Treatment with Encorafenib and Binimetinib in Melanoma Cell Lines

Vikas Patel et al.

Summary: Melanoma is the most aggressive form of skin cancer, and therapy using combined BRAF/MEK inhibitors has shown promise in treating patients with specific mutations. Unfortunately, many patients develop drug resistance to this treatment. This study aimed to characterize the molecular background of acquired resistance and identified various changes in gene and protein expression that contribute to drug resistance in melanoma cells.

CANCERS (2021)

Review Biochemistry & Molecular Biology

Osteopontin Expression in Thyroid Cancer: Deciphering EMT-Related Molecular Mechanisms

Bruna Prunes Pena Baroni Viana et al.

Summary: Thyroid cancer, the most common tumor arising from the endocrine system, typically has a good prognosis, but aggressive subtypes can be resistant to therapy and lead to early metastasis. Epithelial-mesenchymal transition and its reverse, mesenchymal-epithelial transition, play key roles in cancer progression, including in thyroid cancer. Although the matricellular protein osteopontin is known to regulate EMT in various tumor types, its specific role in thyroid cancer has not been definitively established.

BIOMEDICINES (2021)

Article Oncology

Assessing SPP1/Osteopontin (OPN) Splice Variants and Their Association to Nonmelanoma Skin Cancer by Absolute Quantification: Identification of OPN-5 Subvariants and Their Protein Coding Potential

Chu-Fang Chou et al.

Summary: The study evaluated the differential expression of SPP1/osteopontin (OPN) splice variants in nonmelanoma skin cancer compared to normal skin. Higher levels of certain splice variants were found in cutaneous squamous cell carcinomas (cSCCs) and basal cell carcinomas relative to normal skin.

CANCER INVESTIGATION (2021)

Review Oncology

The role of osteopontin in the development and metastasis of melanoma

Yun Zhao et al.

Summary: Melanoma is a highly heterogeneous tumor with poor long-term prognosis, and its treatment options include surgical removal, chemotherapy, and immunotherapy; limited effectiveness is seen in mutated melanoma. Osteopontin, an extracellular protein, plays a key role in the proliferation and invasion of cancer cells, as well as the development of tumor microenvironment, with recent studies clarifying its relationship with melanoma metastasis.

MELANOMA RESEARCH (2021)

Review Oncology

Osteopontin as a Regulator of Colorectal Cancer Progression and Its Clinical Applications

Katyana Amilca-Seba et al.

Summary: The mortality of colorectal cancer is linked to metastatic disease and undetectable micro-metastasis growth. Therapeutic strategies are efficient for locally advanced cancer but struggle to cure metastatic disease due to drug resistance and aggressive phenotype. Osteopontin is emerging as a valuable biomarker in various cancer types, including CRC, and shows potential as a therapeutic target.

CANCERS (2021)

Article Cell Biology

Distinctive Prognostic Value and Cellular Functions of Osteopontin Splice Variants in Human Gastric Cancer

Chengcheng Hao et al.

Summary: The study found that osteopontin (OPN) splice variants have distinct prognostic value in gastric cancer and exhibit unique functions in gastric cancer cells. Specifically, high levels of OPN-a and OPN-b were associated with short overall survival and disease-free survival in gastric cancer patients, while low expression of OPN-c was linked to poor prognosis.

CELLS (2021)

Article Oncology

Silencing Osteopontin Expression Inhibits Proliferation, Invasion and Induce Altered Protein Expression in Melanoma Cells

Timea Kiss et al.

Summary: The study showed that inhibiting OPN expression with siRNA can decrease proliferation and invasion of melanoma cells, affecting the expression of key proteins. Additionally, protein profile analysis and STRING analysis can predict interactions and pathways of these proteins.

PATHOLOGY & ONCOLOGY RESEARCH (2021)

Article Pathology

Melanoma pathology reporting and staging

Richard A. Scolyer et al.

MODERN PATHOLOGY (2020)

Review Dermatology

The role of integrins in melanoma: a review

Suzette M. Arias-Mejias et al.

INTERNATIONAL JOURNAL OF DERMATOLOGY (2020)

Article Biochemistry & Molecular Biology

Osteopontin-4 and Osteopontin-5 splice variants are expressed in several tumor cell lines

Gabriela Ribeiro Silva et al.

MOLECULAR BIOLOGY REPORTS (2020)

Article Oncology

Subtyping Cutaneous Melanoma Matters

Mary-Ann El Sharouni et al.

JNCI CANCER SPECTRUM (2020)

Review Biochemistry & Molecular Biology

Role of osteopontin in dendritic cell shaping of immune responses

Annalisa Del Prete et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2019)

Review Pharmacology & Pharmacy

Osteopontin as a multifaceted driver of bone metastasis and drug resistance

Xiaocong Pang et al.

PHARMACOLOGICAL RESEARCH (2019)

Review Oncology

Osteopontin as a biomarker for osteosarcoma therapy and prognosis

Xingwen Han et al.

ONCOLOGY LETTERS (2019)

Review Biochemistry & Molecular Biology

Regulation and functions of integrin α2 in cell adhesion and disease

Valery Adorno-Cruz et al.

GENES & DISEASES (2019)

Review Oncology

Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma

Ruixia Huang et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)

Article Medicine, Research & Experimental

Human osteopontin: Potential clinical applications in cancer

Chengcheng Hao et al.

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2017)

Review Biochemistry & Molecular Biology

Osteopontin splice variants and polymorphisms in cancer progression and prognosis

Marco Antonio Briones-Orta et al.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2017)

Review Oncology

Alpha2beta1 integrin in cancer development and chemoresistance

Dalila Naci et al.

SEMINARS IN CANCER BIOLOGY (2015)

Article Oncology

The role of osteopontin expression in melanoma progression

Timea Kiss et al.

TUMOR BIOLOGY (2015)

Article Multidisciplinary Sciences

Intracellular osteopontin regulates homeostasis and function of natural killer cells

Jianmei W. Leavenworth et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)

Article Endocrinology & Metabolism

Tertiary structure prediction and identification of druggable pocket in the cancer biomarker - Osteopontin-c

Subramaniam Sivakumar et al.

JOURNAL OF DIABETES AND METABOLIC DISORDERS (2014)

Article Multidisciplinary Sciences

Integrative Genomics Identifies Gene Signature Associated with Melanoma Ulceration

Zsuzsa Rakosy et al.

PLOS ONE (2013)

Article Immunology

Intracellular osteopontin (iOPN) and immunity

Makoto Inoue et al.

IMMUNOLOGIC RESEARCH (2011)

Article Biochemistry & Molecular Biology

Osteopontin Undergoes Polymerization in Vivo and Gains Chemotactic Activity for Neutrophils Mediated by Integrin α9β1

Norihisa Nishimichi et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2011)

Article Medicine, Research & Experimental

The alpha(2)beta(1) integrin is a metastasis suppressor in mouse models and human cancer

Norma E. Ramirez et al.

JOURNAL OF CLINICAL INVESTIGATION (2011)

Article Oncology

Osteopontin-c Splicing Isoform Contributes to Ovarian Cancer Progression

Tatiana M. Tilli et al.

MOLECULAR CANCER RESEARCH (2011)

Review Cell Biology

Role of the metastasis-promoting protein osteopontin in the tumour microenvironment

Pieter H. Anborgh et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)

Article Oncology

Integrin α2 Mediates Selective Metastasis to the Liver

Kiyoshi Yoshimura et al.

CANCER RESEARCH (2009)

Article Peripheral Vascular Disease

Osteopontin: A multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification

Hyun-Ju Cho et al.

CURRENT ATHEROSCLEROSIS REPORTS (2009)

Article Oncology

Osteopontin as a molecular prognostic marker for melanoma

Javier Rangel et al.

CANCER (2008)